Vitura Health Limited · ASX:VIT
Vitura Health — FY2025 Earnings Presentation
30 slides from Vitura Health's earnings presentation, Aug 27, 2025
Slide 1: FY2025 financial results investor webinar and presentation
ASX ANNOUNCEMENT FY2025 financial results Investor webinar and presentation 27 AUGUST 2025 Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company), a leading digital health business, is pleased to confirm details of the investor webinar that will be held later today at which the
Slide 2: About Vitura Health Limited
About Vitura Health Limited (ASX: VIT) www.vitura.com.au Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses: • www.burleighheadscannabis.com Burleigh Heads Cannabis operates the market le
Slide 3: Clinics, contact and forward-looking statements
• www.cdaclinics.com.au The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis. • www.cannadoc.com.au The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehe
Slide 4: FY2025 Results Investor Webinar August 2025
For personal use only FY2025 RESULTS INVESTOR WEBINAR 27 AUGUST 2025 GEOFF COCKERILL, CEO TOM HOWITT, CFO COMMERCIAL IN CONFIDENCE 1
Slide 5: Agenda
AGENDA For personal use only • Updated Vision and Mission • Company Overview • FY2025 Highlights, Leadership and Strategy Update • Operational Overview • Financial Overview • Outlook Vitura Health Limited 2
Slide 6: Vitura has Updated its Vision and Mission ahead of FY2026
Vitura has Updated its Vision and Mission ahead of FY2026 • Recognising the continuing evolution of Vitura, in conjunction with the EBITDA growth For personal use only reported in FY2025, the business has updated its guiding Vision and Mission for FY2026. Vision // • Together, these important statem
Slide 7: Company Overview
For personal use only COMPANY OVERVIEW
Slide 8: Vitura's unique digital health ecosystem
Vitura’s unique digital health ecosystem • Fully integrated end-to-end digital health platform with services at every step of the patient journey from GP consulting to medication dispensing. For personal use only • Distribution, logistics and route to market services for licensed wholesale supply of
Slide 9: Our Growing Portfolio of Interconnected Brands
Vitura Overview - Our Growing Portfolio of Interconnected Brands For personal use only Vitura Health Limited 6
Slide 10: Operational Segmentation
Vitura Overview – Operational Segmentation Vitura’s operations are divided into five interrelated segments enabling it to participate in each step of the doctor, patient, pharmacist and supplier ecosystem. For personal use only General Practice Clinic Specialty Clinics Joint Venture Clinics Products
Slide 11: Company Information (as at August 2025)
Company Information (as at 25 August 2025) Shares On Issue 662,254,856 For personal use only Market Capitalisation (at 7.0 cents) $46.4M Charlie Shahin AO (17.29%) Guy Headley (15.07%) Substantial Shareholders Sarah Jansen (12.93%) Cronos Group Inc. (8.33%) Matua Jansen (5.45%) Robert Iervasi (Chair
Slide 12: FY2025 Financial Highlights
FY2025 FINANCIAL HIGHLIGHTS For personal use only
Slide 13: FY2025 Financial Results - Summary
FY2025 Financial Results - Summary YOY CHANGE A$M FY2025 FY2024 (%) For personal use only Operating revenue 124.04 123.87 0.14 EBITDA 7.63 6.18 23.5 Normalised EBITDA 8.81 8.38 5.1 NPAT 3.06 3.25 5.8 Normalised NPAT 3.88 4.77 18.6 Normalised earnings per share (cents) 0.64 0.84 23.8 Notes: • Normali
Slide 14: FY2025 Financial Results - Highlights
FY2025 Financial Results - Highlights Key Points For personal use only • Strong EBITDA growth and dividend o EBITDA $7.63 million (FY2024: $6.18 million) - UP 23.5% o Normalised EBITDA $8.81 million (FY2024: $8.38 million) - UP 5.1% o Operating expenses reduced by $640,000 o Fully franked dividend o
Slide 15: FY2025 Financial Results – Highlights (cont.)
FY2025 Financial Results – Highlights (cont.) Key Points For personal use only • Doctors on Demand growth continues o Annualised revenue for July 2025 exceeded $32 M – UP 26% vs PCP • Strategic investment by Professor Khalil (Charlie) Shahin AO o Initial $5.1M investment (Feb 2025) and further share
Slide 16: New Senior Appointments – Focus on Execution
New Senior Appointments – Focus on Execution New Directors New Executives For personal use only Daniel Birch, Independent Non-Executive Director Geoffrey Cockerill, Chief Executive Officer • Appointed 27 November 2024 • Commenced 25 November 2024 Gerard Fogarty AO, Independent Non-Executive Director
Slide 17: Strategy Reset – Now Executing
Strategy Reset – Now Executing For personal use only STRENGTHEN MARKET EXPAND CUSTOMER TECHNOLOGY FINANCIAL POSITION AND MARKET BASE ENHANCEMENT IMPROVEMENT • Market leadership in • Increase customer • Enhance and expand • Disciplined approach MC, nicotine vaping and retention and Doctors On Demand
Slide 18: Operational Overview
For personal use only OPERATIONAL OVERVIEW
Slide 19: Canview – a recognised leader in the Market
Canview – a recognised leader in the Market • Vitura’s centralised technology platform is Canview • Full acquisition of Canview platform copy completed in February For personal use only 2025 delivering enhanced patient–script–medication connectivity • Canview continues to gain traction, with over 90
Slide 20: Doctors on Demand – a leader in Australian telehealth
Acquisitions Doctors Driving– Growth on Demand a leader–inDoctors on telehealth Australian Demand • Doctors on Demand (DoD) acquired by Vitura in October 2023 • Offers 24/7 nationwide general practice telehealth services, 365 For personal use only days a year • More than 350 doctors providing consul
Slide 21: Acquisitions Driving Growth – Candor and Releaf
Acquisitions Driving Growth – Candor and Releaf • Vitura acquired Candor Medical, one of Australia’s leading medicinal cannabis clinics, in February 2025 For personal use only • Acquisition brings up to an additional 15,000 patients through a fully integrated digital platform • Candor now forms the
Slide 22: Synergies continue to be realised
Synergies continue to be realised • Vitura’s CDA Clinics and Cannadoc Health businesses now successfully migrated to Candor’s fully integrated platform For personal use only • Ensures patients receive a consistent, modern and expanded telehealth service, with improved patient care • Assets of Heyday
Slide 23: FY2025 Detailed Financials
FY2025 DETAILED FINANCIALS For personal use only
Slide 24: FY2025 revenue and earnings
FY2025 revenue and earnings • Revenue for FY2025 up slightly by 0.14% Total revenue for FY2025 of $124.0M • Consulting and service fees rose strongly by 80% For personal use only Comprising: • Recently acquired businesses (Candor, Releaf and • Sales and distribution: $96.3M Heyday) continue to diver
Slide 25: Cashflow and net cash
Cashflow and net cash For personal use only • During FY2025, cash receipts from customers (including GST) were $134.8M • This represented an increase of $2.9M (or just over 2%) on the PCP • Net cash flows from operations decreased by more than 62% during the year, due to the 7% increase in payments
Slide 26: FY2025 Balance Sheet
FY2025 Balance Sheet • Cash and cash equivalents decreased by $3.77M, or 33% compared to PCP For personal use only • Main drivers included: o $6.25M final payment for Doctors on Demand o $3.11M net acquisition cost of Candor Medical o $4.43M investment in net intangible assets • Offset by: o $5.17M
Slide 27: FY2025 Growth Preparing Vitura for Strong FY2026
FY2025 Growth Preparing Vitura for Strong FY2026 • In FY2025, Vitura achieved growth in revenue, EBITDA margin and OPEX efficiency, with EBITDA up 23.5% year-on-year and total OPEX falling by $640,000, despite several key acquisitions made during the year. For personal use only • In FY2026, Vitura i
Slide 28: Investment thesis remains strong
Investment thesis remains strong • New leadership team executing well against strategic reset • Proven delivery of initiatives and execution in the marketplace For personal use only • New acquisitions integrating well for consistent patient experience • Medical consulting numbers and service fees ri
Slide 29: Disclaimer applying to this Presentation
Disclaimer applying to this Presentation The following disclaimer applies to this presentation (Presentation) You are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this Presentation. This Presentation h
Slide 30: Vitura Health Limited contact
For personal use only vitura.com.au VITURA HEALTH LIMITED ASX : VIT info@vitura.com.au 1300 799 491